These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
152 related articles for article (PubMed ID: 36938892)
1. Phase II study of dose-adjusted EPOCH as initial therapy for adults with high-risk acute lymphoblastic leukemia. Cassaday RD; Zarling LC; Garcia KA; Sala-Torra O; Stevenson PA; Martino CH; Liu YJ; Fang M; Percival MM; Halpern AB; Becker PS; Oehler VG; Shustov AR; Cooper JP; Orozco JJ; Hendrie PC; Walter RB; Radich JP; Soma LA; Estey EH Leuk Lymphoma; 2023 May; 64(5):927-937. PubMed ID: 36938892 [TBL] [Abstract][Full Text] [Related]
2. Interferon alfa-2b in patients with low-grade lymphomatoid granulomatosis and chemotherapy with DA-EPOCH-R in patients with high-grade lymphomatoid granulomatosis: an open-label, single-centre, phase 2 trial. Melani C; Dowdell K; Pittaluga S; Dunleavy K; Roschewski M; Song JY; Calattini S; Kawada JI; Price DA; Chattopadhyay PK; Roederer M; Lucas AN; Steinberg SM; Jaffe ES; Cohen JI; Wilson WH Lancet Haematol; 2023 May; 10(5):e346-e358. PubMed ID: 37011643 [TBL] [Abstract][Full Text] [Related]
3. Long-term follow-up of dose-adjusted EPOCH plus rituximab (DA-EPOCH-R) in untreated patients with poor prognosis large B-cell lymphoma. A phase II study conducted by the Spanish PETHEMA Group. Purroy N; Bergua J; Gallur L; Prieto J; Lopez LA; Sancho JM; García-Marco JA; Castellví J; Montes-Moreno S; Batlle A; de Villambrosia SG; Carnicero F; Ferrando-Lamana L; Piris MA; Lopez A Br J Haematol; 2015 Apr; 169(2):188-98. PubMed ID: 25521006 [TBL] [Abstract][Full Text] [Related]
4. Hyper-CVAD versus dose-adjusted EPOCH as initial treatment for adults with acute lymphoblastic leukemia. Zarling LC; Stevenson PA; Soma LA; Martino CH; Percival MM; Halpern AB; Ghiuzeli CM; Becker PS; Oehler VG; Cooper JP; Orozco JJ; Hendrie PC; Walter RB; Estey EH; Cassaday RD Eur J Haematol; 2023 Dec; 111(6):863-871. PubMed ID: 37670560 [TBL] [Abstract][Full Text] [Related]
5. Outcomes of the cyclophosphamide, vincristine, prednisone (CVP) +/- rituximab (R-CVP) regimen in older patients with newly diagnosed Ph- acute lymphoblastic leukemia. Saygin C; Grieselhuber N; Blachly J; Byrd JC; Vasu S; Larkin K; Behbehani G; Long M; Walker A; Bhatnagar B; Mims A Leuk Res; 2020 Feb; 89():106297. PubMed ID: 31935625 [No Abstract] [Full Text] [Related]
6. Low-intensity therapy in adults with Burkitt's lymphoma. Dunleavy K; Pittaluga S; Shovlin M; Steinberg SM; Cole D; Grant C; Widemann B; Staudt LM; Jaffe ES; Little RF; Wilson WH N Engl J Med; 2013 Nov; 369(20):1915-25. PubMed ID: 24224624 [TBL] [Abstract][Full Text] [Related]
7. Phase 1 study of lenalidomide plus dose-adjusted EPOCH-R in patients with aggressive B-cell lymphomas with deregulated MYC and BCL2. Godfrey JK; Nabhan C; Karrison T; Kline JP; Cohen KS; Bishop MR; Stadler WM; Karmali R; Venugopal P; Rapoport AP; Smith SM Cancer; 2019 Jun; 125(11):1830-1836. PubMed ID: 30707764 [TBL] [Abstract][Full Text] [Related]
8. R-CODOX-M/R-IVAC versus DA-EPOCH-R in patients with newly diagnosed Burkitt lymphoma (HOVON/SAKK): final results of a multicentre, phase 3, open-label, randomised trial. Chamuleau MED; Stenner F; Chitu DA; Novak U; Minnema MC; Geerts P; Stevens WBC; Zenz T; van Imhoff GW; Wu KL; Demandt AMP; Kersten MJ; Terpstra WE; Tick LW; Deeren D; Van Den Neste E; Gregor M; Veelken H; Böhmer LH; Caspar CB; Mutsaers P; Refos JM; Sewsaran R; Fu L; Seefat RL; Uyl-de Groot CA; Dirnhofer S; Van Den Brand M; de Jong D; Nijland M; Lugtenburg P Lancet Haematol; 2023 Dec; 10(12):e966-e975. PubMed ID: 37922925 [TBL] [Abstract][Full Text] [Related]
9. Venetoclax with dose-adjusted EPOCH-R as initial therapy for patients with aggressive B-cell lymphoma: a single-arm, multicentre, phase 1 study. Rutherford SC; Abramson JS; Bartlett NL; Barta SK; Khan N; Joyce R; Maddocks K; Ali-Shaw T; Senese S; Yuan Y; Westin J; Leonard JP Lancet Haematol; 2021 Nov; 8(11):e818-e827. PubMed ID: 34634256 [TBL] [Abstract][Full Text] [Related]
16. Final report of a phase II study of imatinib mesylate with hyper-CVAD for the front-line treatment of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Daver N; Thomas D; Ravandi F; Cortes J; Garris R; Jabbour E; Garcia-Manero G; Borthakur G; Kadia T; Rytting M; Konopleva M; Kantarjian H; O'Brien S Haematologica; 2015 May; 100(5):653-61. PubMed ID: 25682595 [TBL] [Abstract][Full Text] [Related]
17. A comparison of R-EPOCH and R-CHOP as a first-line regimen in de novo DLBCL patients with high Ki-67 expression in a single institution. Huang JJ; Xia Y; Wang Y; Liu PP; Bi XW; Sun P; Lin TY; Jiang WQ; Li ZM Oncotarget; 2016 Jul; 7(27):41242-41250. PubMed ID: 27183909 [TBL] [Abstract][Full Text] [Related]
18. A single-institution retrospective analysis of outcomes for stage I-II primary mediastinal large B-cell lymphoma treated with immunochemotherapy with or without radiotherapy. Binkley MS; Hiniker SM; Wu S; Natkunam Y; Mittra ES; Advani RH; Hoppe RT Leuk Lymphoma; 2016; 57(3):604-8. PubMed ID: 26159046 [TBL] [Abstract][Full Text] [Related]
19. Dose-adjusted EPOCH-R (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab) in untreated aggressive diffuse large B-cell lymphoma with MYC rearrangement: a prospective, multicentre, single-arm phase 2 study. Dunleavy K; Fanale MA; Abramson JS; Noy A; Caimi PF; Pittaluga S; Parekh S; Lacasce A; Hayslip JW; Jagadeesh D; Nagpal S; Lechowicz MJ; Gaur R; Lucas A; Melani C; Roschewski M; Steinberg SM; Jaffe ES; Kahl B; Friedberg JW; Little RF; Bartlett NL; Wilson WH Lancet Haematol; 2018 Dec; 5(12):e609-e617. PubMed ID: 30501868 [TBL] [Abstract][Full Text] [Related]